Combination therapy for mucormycosis

Why, what, and how?

Brad Spellberg, Ashraf Ibrahim, Emmanuel Roilides, Russel E. Lewis, Olivier Lortholary, George Petrikkos, Dimitrios P. Kontoyiannis, Thomas J. Walsh

Research output: Contribution to journalArticle

Abstract

The high mortality rate of mucormycosis with currently available monotherapy, particularly in hematology patients, has stimulated interest in studying novel combinations of antifungal agents to determine whether superior outcomes might be achieved. Combination lipid polyene-echinocandin therapy is the most promising of such regimens based on safety profile, the availability of parenteral formulations of echinocandins, their synergy in murine models of mucormycosis, and observational clinical data that are concordant. Other options include combination lipid polyene plus deferasirox or posaconazole therapy. Definitive, randomized, placebo-controlled phase III clinical trials are needed to determine whether combination therapy with any of these options is superior to monotherapy. Until such studies are conducted, clinicians will continue to be placed in the unacceptable position of not knowing if and when to administer combination therapy. Such a state of confusion may lead to undertreatment if combination therapy is indeed superior but is not used and, conversely, may lead to unacceptable toxicity and cost to patients if combination therapy is not superior but is used. It is critical that sponsors step forward with funding to conduct these clinical trials to determine whether outcomes from these devastating infections can be improved.

Original languageEnglish (US)
JournalClinical Infectious Diseases
Volume54
Issue numberSUPPL. 1
DOIs
StatePublished - Feb 1 2012
Externally publishedYes

Fingerprint

Mucormycosis
Echinocandins
Polyenes
Therapeutics
Lipids
Phase III Clinical Trials
Antifungal Agents
Controlled Clinical Trials
Hematology
Placebos
Clinical Trials
Safety
Costs and Cost Analysis
Mortality
Infection

ASJC Scopus subject areas

  • Infectious Diseases
  • Microbiology (medical)

Cite this

Spellberg, B., Ibrahim, A., Roilides, E., Lewis, R. E., Lortholary, O., Petrikkos, G., ... Walsh, T. J. (2012). Combination therapy for mucormycosis: Why, what, and how? Clinical Infectious Diseases, 54(SUPPL. 1). https://doi.org/10.1093/cid/cir885

Combination therapy for mucormycosis : Why, what, and how? / Spellberg, Brad; Ibrahim, Ashraf; Roilides, Emmanuel; Lewis, Russel E.; Lortholary, Olivier; Petrikkos, George; Kontoyiannis, Dimitrios P.; Walsh, Thomas J.

In: Clinical Infectious Diseases, Vol. 54, No. SUPPL. 1, 01.02.2012.

Research output: Contribution to journalArticle

Spellberg, B, Ibrahim, A, Roilides, E, Lewis, RE, Lortholary, O, Petrikkos, G, Kontoyiannis, DP & Walsh, TJ 2012, 'Combination therapy for mucormycosis: Why, what, and how?', Clinical Infectious Diseases, vol. 54, no. SUPPL. 1. https://doi.org/10.1093/cid/cir885
Spellberg B, Ibrahim A, Roilides E, Lewis RE, Lortholary O, Petrikkos G et al. Combination therapy for mucormycosis: Why, what, and how? Clinical Infectious Diseases. 2012 Feb 1;54(SUPPL. 1). https://doi.org/10.1093/cid/cir885
Spellberg, Brad ; Ibrahim, Ashraf ; Roilides, Emmanuel ; Lewis, Russel E. ; Lortholary, Olivier ; Petrikkos, George ; Kontoyiannis, Dimitrios P. ; Walsh, Thomas J. / Combination therapy for mucormycosis : Why, what, and how?. In: Clinical Infectious Diseases. 2012 ; Vol. 54, No. SUPPL. 1.
@article{928b10ab8e0a4d308a4f87b9bc5efd56,
title = "Combination therapy for mucormycosis: Why, what, and how?",
abstract = "The high mortality rate of mucormycosis with currently available monotherapy, particularly in hematology patients, has stimulated interest in studying novel combinations of antifungal agents to determine whether superior outcomes might be achieved. Combination lipid polyene-echinocandin therapy is the most promising of such regimens based on safety profile, the availability of parenteral formulations of echinocandins, their synergy in murine models of mucormycosis, and observational clinical data that are concordant. Other options include combination lipid polyene plus deferasirox or posaconazole therapy. Definitive, randomized, placebo-controlled phase III clinical trials are needed to determine whether combination therapy with any of these options is superior to monotherapy. Until such studies are conducted, clinicians will continue to be placed in the unacceptable position of not knowing if and when to administer combination therapy. Such a state of confusion may lead to undertreatment if combination therapy is indeed superior but is not used and, conversely, may lead to unacceptable toxicity and cost to patients if combination therapy is not superior but is used. It is critical that sponsors step forward with funding to conduct these clinical trials to determine whether outcomes from these devastating infections can be improved.",
author = "Brad Spellberg and Ashraf Ibrahim and Emmanuel Roilides and Lewis, {Russel E.} and Olivier Lortholary and George Petrikkos and Kontoyiannis, {Dimitrios P.} and Walsh, {Thomas J.}",
year = "2012",
month = "2",
day = "1",
doi = "10.1093/cid/cir885",
language = "English (US)",
volume = "54",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Combination therapy for mucormycosis

T2 - Why, what, and how?

AU - Spellberg, Brad

AU - Ibrahim, Ashraf

AU - Roilides, Emmanuel

AU - Lewis, Russel E.

AU - Lortholary, Olivier

AU - Petrikkos, George

AU - Kontoyiannis, Dimitrios P.

AU - Walsh, Thomas J.

PY - 2012/2/1

Y1 - 2012/2/1

N2 - The high mortality rate of mucormycosis with currently available monotherapy, particularly in hematology patients, has stimulated interest in studying novel combinations of antifungal agents to determine whether superior outcomes might be achieved. Combination lipid polyene-echinocandin therapy is the most promising of such regimens based on safety profile, the availability of parenteral formulations of echinocandins, their synergy in murine models of mucormycosis, and observational clinical data that are concordant. Other options include combination lipid polyene plus deferasirox or posaconazole therapy. Definitive, randomized, placebo-controlled phase III clinical trials are needed to determine whether combination therapy with any of these options is superior to monotherapy. Until such studies are conducted, clinicians will continue to be placed in the unacceptable position of not knowing if and when to administer combination therapy. Such a state of confusion may lead to undertreatment if combination therapy is indeed superior but is not used and, conversely, may lead to unacceptable toxicity and cost to patients if combination therapy is not superior but is used. It is critical that sponsors step forward with funding to conduct these clinical trials to determine whether outcomes from these devastating infections can be improved.

AB - The high mortality rate of mucormycosis with currently available monotherapy, particularly in hematology patients, has stimulated interest in studying novel combinations of antifungal agents to determine whether superior outcomes might be achieved. Combination lipid polyene-echinocandin therapy is the most promising of such regimens based on safety profile, the availability of parenteral formulations of echinocandins, their synergy in murine models of mucormycosis, and observational clinical data that are concordant. Other options include combination lipid polyene plus deferasirox or posaconazole therapy. Definitive, randomized, placebo-controlled phase III clinical trials are needed to determine whether combination therapy with any of these options is superior to monotherapy. Until such studies are conducted, clinicians will continue to be placed in the unacceptable position of not knowing if and when to administer combination therapy. Such a state of confusion may lead to undertreatment if combination therapy is indeed superior but is not used and, conversely, may lead to unacceptable toxicity and cost to patients if combination therapy is not superior but is used. It is critical that sponsors step forward with funding to conduct these clinical trials to determine whether outcomes from these devastating infections can be improved.

UR - http://www.scopus.com/inward/record.url?scp=84855883479&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855883479&partnerID=8YFLogxK

U2 - 10.1093/cid/cir885

DO - 10.1093/cid/cir885

M3 - Article

VL - 54

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - SUPPL. 1

ER -